Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020

HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

Unmet Needs in the Management of HER2+ mBC

January 11th 2020

Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Oncology Leader Thomas J. Lynch Jr. Appointed as New Fred Hutch President and Director

January 8th 2020

Internationally renowned medical oncologist Thomas J. Lynch Jr, MD, has been named the new president and director of the Fred Hutchinson Cancer Research Center.

On the Radar for 2020: Oncology Experts Weigh In on Key Trends

January 7th 2020

After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains.

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30th 2019

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.

FDA Accepts Sacituzumab Govitecan Application for TNBC

December 27th 2019

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

Fellows Take Top Prizes in OncLive Innovation Challenge

December 25th 2019

A pair of fellows will be able to advance their innovative technology-based projects thanks to the OncLive® Innovation Challenge: Innovative Technology in Cancer Care.

Incorporating PROs Can Improve Patient Care and Outcomes in Oncology

November 30th 2019

Karnofsky Performance Status and ECOG performance status alone leaves a lot to be desired for the practicing oncologist.